Arbutus生物制药 ABUS 深 沪
等待开盘 05-11 09:30:00 美东时间
4.34
-0.010
-0.23%
华盛通- 最 高4.40
- 今 开4.34
- 成交量 75.29万股
- 最 低 4.309
- 昨 收 4.35
- 总市值 8.55亿
- 52周最高 5.10
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 3.04
- 委 比 6.43%
- 总股本 1.97亿
- 历史最高 31.48
- 量 比 0.89
- 振 幅 2.09%
- 历史最低 0.821
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales
UPDATE 1-Moderna tops revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to decline
05-01 18:38
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales International sales outpace US as partnerships boost revenue Q1 net loss includes charge from patent settlement with Genevant, Arbutus Moderna forecasts 10% revenue growth in 2026, with US share expected to declin
05-01 18:30
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
04-22 01:58
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA") has
04-15 19:33
Arbutus says FDA grants Fast Track designation for hepatitis B drug imdusiran
Arbutus says FDA grants Fast Track designation for hepatitis B drug imdusiran Arbutus Biopharma disclosed FDA Fast Track designation for imdusiran in chronic hepatitis B. Trial results were already presented, showing some patients reached a functional cure or stopped medication. Fast Track status co
04-15 19:32
Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B
Arbutus says FDA grants Fast Track designation for imdusiran in chronic hepatitis B FDA granted Fast Track designation to Arbutus for imdusiran to treat chronic hepatitis B. Designation could speed development and FDA review for the program. Disclaimer: This news brief was created by Public Technolo
04-15 19:31
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 85.71 percent increase over losses of $(0.07) per share from
03-23 19:44
Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment
Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment Arbutus said it is developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, positioning the company to compete in combination regimens aimed at improving treatment outcomes. Management stated that more than 20
03-23 19:32
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma reported strong financial results for 2025, with $91.5M in cash and marketable securities. The company achieved a significant milestone with a $950M settlement from Moderna for LNP technology infringement. Additionally, two more patients in the Phase 2a trials of imdusiran achieved functional cure for chronic hepatitis B. The company also received a milestone payment for its HCC treatment candidate. Financial performance showed ...
03-23 11:30
美股机会日报 | 传伊朗特工秘密接触中情局！并讨论停火价码；美财长贝森特称15%关税本周内将实施
传伊朗特工秘密接触中情局！纳指期货盘前拉升涨0.6%；美财长贝森特称15%关税本周内将实施；比特币重回7.1万美元上方！加密货币概念股普涨，Strategy涨近7%>>
03-04 21:16
